In early August 2026, Merck reported second-quarter sales of US$16,607 million and a net loss of US$1,335 million, raised its ...

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

Dr. Lori Ross, DVM, is an emergency veterinarian at Emergency Veterinary Care Centers (EVCC) and a veterinary leader with more than 15 years of experience in emergency and critical… Heartworm disease ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Competition is pumping up around ...

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term ...

Merck confronts an approaching Keytruda patent cliff and is broadening its pipeline across oncology, vaccines and ...

Merck & Co. boosted its 2026 sales outlook after strong demand for newer drugs like Winrevair helped to drive revenues higher in the second quarter. Sales will be between $66.3 billion and $67.3 ...

The same anger that surrounded the Covid-19 pandemic was back again this week as Anthony Fauci testified on Capitol Hill.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestitures have strengthened its position across these ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Heart disease is the leading cause of death for men and women in the ...

For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on ...

Statins are a standard drug for managing high cholesterol, but for patients who need something stronger, a newer class of medicines has become another option. In the more than a decade since these ...